COX-2:0.13 μM (IC50)
COX-1:7.5 μM (IC50)
DMSO:≥52mg / mL(154.58 mM)
* “≥”表示可溶,但飽和度未知。
4°C,避光,在氮?dú)庀聝Υ?/p>
[1]. McCann ME, et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. Am J Vet Res. 2005 Jul;66(7):1278-84.
[2]. Steagall PV, et al. Evaluation of the adverse effects of oral firocoxib in healthy dogs. J Vet Pharmacol Ther. 2007 Jun;30(3):218-23.
[3]. Stock ML, et al. Pharmacokinetics of firocoxib in preweaned calves after oral and intravenous administration. J Vet Pharmacol Ther. 2014 Oct;37(5):457-63.
[4]. Albanese F, et al. Clinical outcome and cyclo-oxygenase-2 expression in five dogs with solar dermatitis/actinic keratosis treated with firocoxib. Vet Dermatol. 2013 Dec;24(6):606-12, e147.
河北方乾新材料科技有限公司
聯(lián)系商家時(shí)請?zhí)峒癱hemicalbook,有助于交易順利完成!